- Home
- GMM vs ALGS Comparison
GMM vs ALGS Comparison
Compare GMM & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GMM | ALGS |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 57.2M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GMM | ALGS |
|---|---|---|
| Price | $1.34 | $9.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 15.8K | ★ 76.5K |
| Earning Date | 08-18-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.75 | ★ N/A |
| Revenue Growth | ★ 41.74 | N/A |
| 52 Week Low | $1.23 | $3.76 |
| 52 Week High | $4.97 | $46.80 |
Technical Indicators
Market Signals| Indicator | GMM | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 30.01 | 62.82 |
| Support Level | $1.25 | $9.10 |
| Resistance Level | $1.59 | $10.45 |
| Average True Range (ATR) | 0.09 | 0.69 |
| MACD | -0.02 | 0.25 |
| Stochastic Oscillator | 28.21 | 87.93 |
Price Performance
Historical ComparisonAbout GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.